AstraZeneca Pharma India Limited has informed the Exchange regarding Notice of Postal Ballot
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India has issued a Postal Ballot Notice seeking shareholder approval for two material related party transactions with its group entities for FY 2026-27. Item 1 is for transactions worth up to ₹2,400 crore with AstraZeneca UK Limited (the ultimate parent), covering purchase/transfer of products, goods, materials, and services — this represents 140% of the company's FY24-25 turnover. Item 2 is for transactions worth up to ₹1,500 crore with AstraZeneca AB, Sweden (the immediate holding company), representing 87% of FY24-25 turnover. Combined, the company is seeking approval for up to ₹3,900 crore of intra-group transactions. Both are flagged as material because they exceed 10% of annual turnover under SEBI rules. The Audit Committee has reviewed and approved the proposals, and the transactions are described as being at arm's length. E-voting runs from February 28, 2026 (9:00 AM IST) to March 29, 2026 (5:00 PM IST), with a cut-off date of February 20, 2026.
These are operational transactions with the company's own parent and holding entities, essential for its day-to-day business of importing and selling pharma products in India. Shareholder approval is procedural but legally required because of the large size relative to turnover. Since the promoter group (AstraZeneca) controls most voting rights, approval is virtually assured. No material change in business outlook — this is a routine annual governance exercise.